ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 780

The Relationship of Inflammation, Fatty Degeneration and the Effect of Long-Term TNF-Blocker Treatment On the Development of New Bone Formation in Patients with Ankylosing Spondylitis

Xenofon Baraliakos1, Frank Heldmann2, Joachim Listing3, Johanna Callhoff3, Jürgen Braun2 and EASIC4, 1Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3German Rheumatism Research Center, Berlin, Germany, 4Herne, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and infliximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Clinical trial results suggest that new bone formation is neither inhibited nor augmented by anti-TNF agents in ankylosing spondylitis (AS). Recently, a potential role of different inflammatory lesions such as inflammation (INF) and fatty degeneration (FD) to predict new bone formation in patients with active AS was suggested. This is the first study to analyze the relationship between INF and FD as assessed by magnetic resonance imaging (MRI) and syndesmophyte formation as assessed by conventional radiography in vertebral edges (VE) of AS patients under long-term anti-TNF treatment.

Methods: Images were scored blinded for the time point of investigation of MRIs and x-rays of patients who participated in the EASIC Registry. Most patients were treated with infliximab. Presence or absence of INF, FD and syndesmophytes was documented on the level of VEs in the anterior part of the spine at each time point. Data were compared using Fisher´s exact test after adjustment for within-patient variation. Relative risk (RR) calculation based on a general linear model and Poisson variation.

Results: Complete sets of MRIs of 73 AS patients were evaluated at BL and 2y (1,526 VEs, 89 with and 1,437 without syndesmophytes or ankylosis at BL) and were related to complete sets of conventional radiographs of the same patients at BL, 2y and 5y. The amount of VEs with INF decreased significantly from 22.5% at BL to 1.5% after 2y, while in contrast, the amount of VEs with FD increased from 23.9% (n=364) at BL to 32.4% at 2y. In parallel, the VEs with syndesmophytes increased from 5.3% to 7.7% between BL and 2y. Overall, 35 and 60 new syndesmophytes developed after 2y and 5y, respectively, from VEs without baseline radiographic damage. The most frequent MRI pathology for syndesmophyte development at BL was the parallel occurrence of both MRI lesions, INF and FD: 22.9% and 16.7% at 2y and 5y, respectively. On the other hand, most of the new syndesmophytes (57.1% after 2y and 58.3% after 5y) seen on radiographs showed neither FD nor INF at BL. Syndesmophyte occurrence at baseline was the only significant predictor for development of these new syndesmophytes. The RR for syndesmophyte development was significant for the occurrence of the FD/INF combination at both follow-up time points, with a RR of 5.0 (p=0.002) after 2y and RR of 3.3 (p=0.009) after 5y, but only if FD lesions remained unchanged under anti-TNF treatment at 2y. On the other hand, no new syndesmophyte developed after 2y or 5y when INF was resolved. Importantly, we saw no new syndesmophyte developing after resolution of inflammation and evolution of new FD at the same VE. 

Conclusion: Both spinal inflammation and fatty degeneration were associated with syndesmophyte development but fatty degeneration showed the highest risk for new syndesmophytes. However, >50% of the new bone formation observed in under anti-TNF treatment over 5 years was not preceded by either one of those. Overall, rather few syndesmophytes developed over 5 years in AS patients treated with anti-TNF. The sequence of INF – FD – new bone formation under anti-TNF was not seen at all. It seems that anti-TNF treatment has a more beneficial effect in the process of bone formation in patients with early (INF) but not late (FD) stages of the disease.


Disclosure:

X. Baraliakos,

Janssen Pharmaceutica Product, L.P.,

2;

F. Heldmann,

Janssen Pharmaceutica Product, L.P.,

2;

J. Listing,
None;

J. Callhoff,
None;

J. Braun,

Janssen Pharmaceutica Product, L.P.,

2;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-of-inflammation-fatty-degeneration-and-the-effect-of-long-term-tnf-blocker-treatment-on-the-development-of-new-bone-formation-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology